Alerts will be sent to your verified email
Verify EmailJUBLPHARMA
Positive for this company
Neutral for this company
Negative for this company
Insufficient data to analyse
Jubilant Pharmova Limited operates globally in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Novel Drugs with a strong manufacturing presence in Radiopharmaceutical products for regulated markets.
Jubilant Pharmova major competitors are Caplin Point Lab, Sanofi India, Natco Pharma, Alembic Pharma, Eris Lifesciences, Pfizer, Marksans Pharma.
Market Cap of Jubilant Pharmova is ₹14,644 Crs.
While the median market cap of its peers are ₹15,034 Crs.
Jubilant Pharmova seems to be less financially stable compared to its competitors.
Altman Z score of Jubilant Pharmova is 3.07 and is ranked 8 out of its 8 competitors.
2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annual Report | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | ||
Earnings Release | Mar Jun Sep Dec | Mar Jun Sep Dec | Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Jun Sep Dec | Jun Sep | Jun Sep | Sep Dec | ||||
Investor Presentation | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Sep Dec | Mar Jun | Mar Jun Sep Dec | ||||
Conference Call | Mar Jun Sep Dec | Mar Jun Sep | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Sep Dec | Jun Sep Dec | ||||||
Conference Call SummaryCon Call Summary
Powered by Gemini
|